The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

• DOI: 10.1186/s12967-019-1828-0
• Publication Date: 2019-03-08T14:03:45Z
• Authors: M. G. Dal Bello; R. A. Filiberti; A. Alama; A. M. Orengo; M. Mussap; S. Coco; I. Vanni; S. Boccardo; E. Rijavec; C. Genova; F. Biello; G. Barletta; G. Rossi; M. Tagliamento; C. Maggioni; F. Grossi
• Keywords: Adult; Male; Lung Neoplasms; Survival; CYFRA21-1; NSCLC; Disease-Free Survival; 03 medical and health sciences; CEA; 0302 clinical medicine; Antigens, Neoplasm; Carcinoma, Non-Small-Cell Lung; Biomarkers, Tumor; Humans; Aged; Neoplasm Staging; Aged, 80 and over; Keratin-19; Research; R; Middle Aged; Carcinoembryonic Antigen; 3. Good health; Nivolumab; Phosphopyruvate Hydratase; Medicine; CEA; CYFRA21-1; Immunotherapy; NSCLC; Survival; Tumor response; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nivolumab; Phosphopyruvate Hydratase; Female; Immunotherapy; Tumor response

CEA, CYFRA21-1 and NSE are tumor markers used for monitoring the response to chemotherapy in advanced adenocarcinoma, squamous cell carcinoma small-cell lung cancer, respectively. Their role cancer immunotherapy needs be elucidated.Patients with non-small (NSCLC) were treated nivolumab 3 mg/kg every 2 weeks within Italian Nivolumab Expanded Access Program. Blood samples collected at baseline, each cycle up 5 then two cycles until patient's withdrawn from study. All patients underwent a CT-scan after 4 of treatment responses classified according RECIST 1.1. The biomarkers serum levels measured chemiluminescent microparticle immunoassay CEA an immuno radiometric assay NSE. values baseline analyze relationship between their variation over response, evaluated as disease control rate (DCR: CR + PR SD), survival (PFS OS).A total 70 evaluable analysis. Overall, was obtained 24 (35.8%, 20 SD). After or reduction ≥ 20% significantly associated DCR (CEA, p = 0.021; CYFRA21-1, < 0.001), PFS 0.028; 0.001) OS 0.026; 0.019). Multivariate analysis confirmed ability predict (p 0.002) 0.001).The level might reliable biomarker efficacy NSCLC patients. not significant nivolumab.